Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Gold, As discussed in previous posts, You always want to compare Onko Sure to Recaf and yet you posted this about Onko Sure... Whats up Gold. You now are admitting that Onko is a much poorer test than Recaf.
Your post in regard to Onko Sure:
"Yes indeed, there is a good reason why the company has very little revenue from sales of Onko Sure and the same reason why no other company would be interested in buying RPC.
How would you like a test that indicated you have cancer when used as a screening test, it gives a false indication of cancer 90% of the time. Are you going to get the necessary additional tests even if it is really a false positive? How many additional tests are required before you either locate the cancer or decide it is a false positive?
Do you understand why doctors have not been using the test to any extent at all since FDA approval to monitor colorectal cancer two and a half years ago?"
http://messages.finance.yahoo.com/Business_%26_Finance/Investments/Stocks_%28A_to_Z%29/Stocks_R/threadview?bn=351&tid=27373&mid=27377
"Their focus in totally on foreign sales for screeing where the false positive rate is a horrendous 10 to 1."
http://messages.finance.yahoo.com/Business_%26_Finance/Investments/Stocks_%28A_to_Z%29/Stocks_R/threadview?bn=351&tid=27316&mid=27328
Gold... Or will we see items that were discussed in the conference...
A third licensee signed, an advancement of the POC test, sales of Dog RECAF and additional progress by Abbott and or Alere...
Gold stated,"Why are the POC tests now relegated to BioCurex China"
Gold, didn't anyone tell you that the popular pregnancy test is made in china?
Would it not make sense to handle the POC in China?
•Components made in China.
•Device assembled in China.
http://webcache.googleusercontent.com/search?q=cache:n4AFYKxzkO8J:milo.com/e-p-t-certainty-1-step-pregnancy-test+where+are+pregnancy+tests+assembled+china&cd=6&hl=en&ct=clnk&gl=us
Cancer Survival Rates in Sweden, Australia Surpass U.K., Denmark in Study
By Chris Kay - Dec 21, 2010 6:30 PM ET inShareMore
Business Exchange Buzz up! Digg Print Email Cancer patients in the U.K. and Denmark are less likely to survive than those living in Australia, Canada, Sweden and Norway because of poorer early diagnosis in the two countries, researchers said. Survival rates for breast, colorectal, lung and ovarian cancer rose in all six countries whose medical data was analyzed in a study published in The Lancet medical journal today. The U.K. and Denmark, which saw the biggest increase in breast cancer survival rates, still lagged behind the other nations.
“The improvement is there to see in all countries,” Michel Coleman, the study’s lead author and a professor of epidemiology and vital statistics at the London School of Hygiene and Tropical Medicine, told reporters at a briefing yesterday in London. “Cancer is a very important chronic disease and public health problem. One in three can be expected to be diagnosed with cancer in our lifetimes and one in four will die of it.”
Patients in the U.K. and Denmark are less likely to be diagnosed in the early stages of disease, when treatment is more effective, based on the one-year survival rates in the study, said Mike Richards, national cancer director at the U.K. Department of Health. Between 2005 and 2007, about 30 percent of Britons were alive within one year of being diagnosed with lung tumors, compared with 35 percent in Denmark, 39 percent in Norway, 42 percent in Canada, 43 percent in Australia and 44 percent in Sweden, the study found.
Improving Diagnosis
Since 2007, the U.K. has focused more on improving tumor detection, Richards said at the London briefing. Britain’s coalition government, led by Prime Minister David Cameron, is attempting to tackle breast, colorectal and lung cancer with a 10.75 million-pound ($16.7 million) awareness campaign beginning in January.
“We have not narrowed the gap effectively for lung, ovarian and colorectal cancers,” he said. “It’s clearly good news that we have narrowed the gap on breast cancer.”
The difference in breast cancer survival narrowed across the six countries to about 5 percentage points in 2005 to 2007, from 9 percentage points in 1995 to 1999, according to the study. While the U.K. and Denmark saw survival rates improve the most, they ranked behind Australia, where 91 percent of patients were alive five years after diagnosis, compared with 86 percent in the U.K. and 87 percent in Denmark, the researchers said.
“I’m optimistic we will see the narrowing of gaps with other countries,” Richards said.
Drug Fund
U.K. Secretary of State for Health Andrew Lansley announced an interim 50 million-pound fund for cancer drugs in October to pay for new treatments not available in the government-run health service until a two-year measure is introduced in April.
The drug fund won’t make a big difference in survival rates in England, Richards said.
“Surgery still remains the treatment that cures the most people,” he said. The study, which examined data from 2.4 million adult patients between 1995 and 2007, was funded by the Department of Health and Cancer Research U.K., a London-based charity.
http://www.bloomberg.com/news/2010-12-21/cancer-survival-rates-in-sweden-canada-surpass-u-k-denmark-in-study.html
To contact the reporter on this story: Chris Kay in London at ckay5@bloomberg.net
To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net
Diagnostic Tests Can Be Patented, U.S. Court Rules
By Susan Decker - Dec 17, 2010 4:05 PM ET
Diagnostic medical tests can be patented, a U.S. appeals court ruled in its first decision on the issue since a landmark Supreme Court case six months ago on business-method patents.
Prometheus Laboratories Inc.’s method of determining the dosage of medicines to treat stomach diseases can be patented, the U.S. Court of Appeals for the Federal Circuit in Washington said. Closely held Prometheus had lost a lower court case in which it sued the Mayo Clinic for infringing two patents. The Federal Circuit reversed the ruling in 2009 and today upheld its decision, saying a judge erred in ruling the patents invalid.
The ruling may aid companies including Myriad Genetics Inc. and Novartis AG, which have tried to capitalize on burgeoning demand for “personalized medicine,” where doctors determine if a patient is genetically susceptible to a particular disease or would be more responsive to certain medicines. Interest in such testing has grown partly as health-benefit companies including Medco Health Solutions Inc. see a way to trim costs.
“It’s a tremendous advance in the whole world of pharmaceuticals if you can better match people with the medicines you give them,” said Jennifer Gordon, a lawyer at Baker Botts in New York who submitted a filing in the case on behalf of Novartis. Companies “want the full capability of getting any type of patent that covers their technology. Patents have been very important to this industry.”
Myriad, which is appealing a federal judge’s ruling in a separate case that invalidated its patents on a test for breast cancer, rose 74 cents, or 3.2 percent, to $23.71 at 4 p.m. New York time in Nasdaq Stock Market composite trading.
Diagnostic Industry Boost
The Prometheus case was being watched to see how the court would interpret a June ruling from the Supreme Court that considered what types of innovations would qualify for legal protection. The Federal Circuit specializes in U.S. patent law.
“The court of appeals is fairly strongly of the view that methods of treatment and methods of diagnostics are patentable all the time,” said Nick Groombridge, a lawyer at Weil, Gotshal in New York who specializes in biotechnology and health patents.
“This is a significant boost for the diagnostic industry,” he said.
The two Prometheus patents are for a method to determine the proper dosage of medicines for ailments including Crohn’s disease or ulcerative colitis to maximize the effectiveness of the drugs while limiting toxic side effects.
Mayo Clinic
The Mayo Clinic, a not-for-profit medical practice based in Rochester, Minnesota, had licensed the patents prior to 2004, when it created its own test using the same metabolites as Prometheus with different levels to determine toxicity. After it was sued, Mayo argued that the patents covered mental steps to look at a body’s natural process, and a judge agreed, saying the subject matter wasn’t eligible for a patent.
Courts had long held that patents can’t be granted for “laws of nature, physical phenomena and abstract ideas.” Prometheus argued that its tests involve an application of a law of nature, not the law itself. The Federal Circuit agreed. The patents “are in effect claims to methods of treatment, which are always transformative when one of a defined group of drugs is administered to the body to ameliorate the effects of an undesired condition,” the three-judge panel ruled.
The Prometheus ruling may help Salt Lake City-based Myriad win its appeal of a judge’s findings that some elements of its patents for diagnosing a woman’s risk of getting breast cancer were simple mental steps. The bulk of the judge’s ruling on Myriad was that isolated DNA is directed to a law of nature and wasn’t an issue in the case ruled upon today.
The case today is Prometheus Laboratories Inc. v. Mayo Collaborative Services, 2008-1403, U.S. Court of Appeals for the Federal Circuit (Washington). The lower court case is Prometheus Lab Inc. v. Mayo Collaborative Services, 04cv1200, U.S. District Court for the Southern District of California (San Diego).
To contact the reporter on this story: Susan Decker in Washington at sdecker1@bloomberg.net.
To contact the editor responsible for this story: Allan Holmes at aholmes25@bloomberg.net.
http://www.bloomberg.com/news/2010-12-17/diagnostic-tests-can-be-patented-u-s-court-rules.html
Gold stated,"Do you realize that YOU are the owners of this company and MORO serves YOU? It is not the other way around."
You never have figured that one out have you Gold...
#1 Dr. Moro also owns shares in this company. In fact he owns more than many of the other shareholders and a hole bunch more than you.
#2 Dr. Moro does not work for anyone...We work together as shareholders.
Gold stated,"BTW, how many times has the company stated that they intend to communicate better with shareholders? Have they done it?"
This depends Gold on one's perception.
Some NON SHAREHOLDERS on this board want to be updated on a day to day or minute to minute basis. They tend to ASSUME and mis-guess many of the ongoings behind the scenes. For these persons,... well they have been and will probably always be dissapointed. These people make it difficult for the company to disseminate information to the true shareholders.
Others listen intently to the news releases and have faith in between the news knowing that we have top quality management in place working to advance the science in efforts to commercialize the products. These people are content with the news that we have received as it has transpired and will be rewarded for their patience.
Alpha-2 integrin: A protein predictor of tumor spread?
Mary Zutter and colleagues, at Vanderbilt University Medical Center, Nashville, have generated data that lead them to suggest that decreased expression of the protein alpha-2 integrin is predictive of tumor dissemination to distant sites and decreased survival in individuals with either breast or prostate cancer.
The researchers first studied the role of the protein alpha-2-beta-1 integrin (which is composed of the alpha-2 integrin protein and the beta-1 integrin protein) in cancer initiation and progression using a clinically relevant, spontaneous mouse model of breast cancer progression and metastasis (spread). Their data indicated that alpha-2-beta-1 integrin suppressed metastasis. To investigate whether the data had any immediate clinical applicability, a systematic analysis of microarray databases of human breast and prostate cancer was performed. The results of this analysis showed that decreased expression of the gene responsible for generating alpha-2 integrin was predictive of metastasis and decreased survival, leading to the suggestion that alpha-2 integrin expression could be a useful biomarker of metastatic potential and patient survival.
Copyright (c) 2010 NewsRx Inc. All Rights Reserved. Designated trademarks and brands are the property of their respective owners. NewsRx is headquartered at 2727 Paces Ferry Suite 2-440, Atlanta, GA 30339. Phone: 770-507-7777 or 800-726-4550; Fax: 770-435-6800; Email: CustomerService@NewsRx.com.
Symbol: BOCX
Analyst: Juan Noble
Taglich Rating: Speculative Buy
Price Target: $0.10 Time Horizon: 12 Months
Rating Established: August 27, 2010
Price When Established: $0.07
Most Recent Report: December 17, 2010
Price When Issued: $0.05
http://www.taglichbrothers.com/equityuniverse/companies/biocurex/biocurex.aspx
Gold stated,"Sometimes you learn more from what is NOT said than what is actually stated."
I know Gold...This is why when you do not answer the questions posed to you most learn a bunch.
Gold stated,"OK, half, now begin with the RECAF test. Where do you go then? That's right, go back to step one with the other tests with the huge number of false positives and negatives. What have you gained with RECAF?"
One would gain the EARLY DETECTION that has been and still is the quest of all Cancer organizations including the NCI.
Gold, one would gain the ability to:
1. Say with a high degree of certainty that he or she does not have cancer.
2. Say with a high degree of certainty that he or she does have cancer.
Or that it has returned or has not returned.
Gold you finally told it like it is!
gold stated,"All of the other tests used to locate a possible cancer also have a huge number of false positives."
They also have huge false negatives !
Current cancer diagnostic tests absolutely suck!
Recaf is way ahead of the current tests !!!!
Gold posted, "I have read extensively."
Gold also stated," Dakota,
I have done extensive research into the technology that RECAF uses and it WORKS. It will be a huge seller and IMO, look for some data to be presented at the July 24th conference in a presentation by the lead developer of the RECAF test at Abbott. Dr. Moro will go down in history as one of the leading developers of cancer detection and treatment.
The personalization aspect of the test is huge. Any developing cancer will cause your RECAF level to dramatically increase. It detects the level of cancer cell division so any change in your normal level is a RED ALERT. Researchers are developing treatments that use the same technology so it does not really matter where the cancer is.
"I have never stated that RECAF could not be used for therapeutics."
"It works like nothing else out there" "I know the test can detect cancer cells."
"I in fact agree that studies show it does detect if cancer is present in the body."
"The test works and was proven at the ISOBM."
"I think that RECAF may get approval to monitor existing cancer "
"BTW, I have always stated that the RECAF test does indeed work."
"The test works as demonstrated at the ISOBM so IMO, there is no more tweeking necessary."
" This is actually a good idea...if everything goes as Moro states, I do think Moro will get revenue from this test. In fact, it may be his best source of revenue for the product period."
BioCurex (BOCX) Stock Trading Info:
For those interested in listening to the conference call please see the following link.
http://www.investorcalendar.com/IC/CEPage.asp?ID=162778
Gold, I believe if I heard it correctly, Alere was having issues regarding the operation of the centrifuge. They were not sure if the potentiometer was to be turned clockwise or counterclockwise. Until this issue was resolved, they were going to delay payment of the annual royalty. To the best of my knowledge, this should be worked out before the end of this year. Rumor has it that they are in negotiations to just remove the potentiometers from all centrifuge units and install RPM selector buttons on them.
This should also satisfy any future Licensees.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=47241207&txt2find=centrifuge
Biocurex also has an appointment set up to run the new synthetic test on equipment belonging to Abbott and Inverness.
Maybe the big guys are ready....
Gold I will take those as rhetorical questions since you still owe me a lot of answers to my previous questions.
You will need to sit back, listen and learn. It will be interesting to see what the stock price does the day of:
a. 510k submission public notice
b. 510k Approval date
c. Third license agreement signing
d. notice of revenue from doggy tests
e. News from Abbott
f. News from Alere
g. Point of care launch
h. Additional distribution announcements
Remember what happened when big old Abbott poked their heads up in the past and when we thought fda had approved recaf,,,,
Could be some money to be made in this one Gold...If you own shares...
I listened to most of the conference call today. I would however like to go back and listen again for more detail and will do so when it is posted. It was very informative.
Biocurex plans ran behind about 6 months but the good part is near now!
FDA 510k approval process will be in first quarter of 2011 (in the next 3 months)for the monitoring of colon cancer. The expense of this approval is low and the process is very quick.
The point of care test similar to the pregnancy test will be available in 2011.
Biocurex will also be meeting with Abbott in January to discuss the use of the new synthetic peptide that recognizes RECAF. The discovery of this synthetic form is patentable which was a stumbling block with regard to Abbott / Inverness (now Alere).
A third Licensee is interested in Recaf and it sounds like they would sign on with similar terms to the previous licensees and would pay the million dollar upfront fee.
Alere does owe a payment to Biocurex for 2010.
The doggy Recaf was being held up by liability issues but this has or is being worked out.
Biocurex does have money for atleast this next year.
Lots more information I recommend that all go back and listen to the conference call.
Gold, is that you buying warrants?
BIOCUREX INC
BOCXW
Stock price
0.02 0.005 +33.33%
Volume traded 851,650
Goldseeker...You are amazing.
To quote you,"It was only about $3,500 but..."
Gold oh Gold Where Art Thou?
Elizabeth Edwards' Family Gathers as Her Cancer Spreads
Elizabeth Edwards was surrounded by her family and friends in North Carolina late Monday as news came that her terminal cancer had spread to her liver.
They found it to late and apparently couldn't monitor it very well either...
Remember when you were so hung up on "finding the location of the cancer" and that Recaf could not locate the cancer in its diagnostic form.
Still looking for your answers. How in the world did breast cancer spread to the liver? Where else did it spread to?
Distant (metastatic): The cancer has spread from the breast to other parts of the body. Cancer tends to move into the lymphatic vessels in the breast. Most lymphatic vessels in the breast drain into lymph nodes in the armpit (axillary lymph nodes). One function of lymph nodes is to filter out and destroy abnormal or foreign cells, such as cancer cells. If cancer cells get past these lymph nodes, the cancer can spread anywhere in the body. Breast cancer can also spread through the bloodstream to other parts of the body. Breast cancer tends to spread to bones and the brain but can spread to any area, including the lungs, liver, skin, and scalp. Breast cancer can appear in these areas years or even decades after it is first diagnosed and treated. If the cancer has spread to one area, it probably has spread to other areas, even if it cannot be detected right away.
http://webcache.googleusercontent.com/search?q=cache:77UkJ3fBVCUJ:www.merckmanuals.com/home/sec22/ch251/ch251f.html+breast+cancer+spread+to+skin&cd=2&hl=en&ct=clnk&gl=us
Gold, Cross one more off of the list. The answer to the question is becoming more clear now. Too bad you couldn't provide the answer when it was originally asked...
See link below
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=41089393&txt2find=natural|causes
Elizabeth Edwards' Family Gathers as Her Cancer Spreads
Elizabeth Edwards was surrounded by her family and friends in North Carolina late Monday as news came that her terminal cancer had spread to her liver.
Elizabeth Edwards, 61, the estranged wife of former presidential contender John Edwards, has battled cancer since 2004. She was diagnosed with breast cancer during the waning weeks of the 2004 presidential election when John Edwards was the vice-presidential nominee for Sen. John Kerry.
The news of Elizabeth Edwards' deterioration was reported by numerous news outlets, including WRAL.com, a website for the Raleigh-Durham area. The website also reported Edwards had recently been hospitalized. Her doctors have said that further treatment would be futile.
"Elizabeth has been advised by her doctors that further treatment of her cancer would be unproductive. She is resting at home with family and friends," the Edwards family says in a statement to PEOPLE.
Elizabeth Edwards posted a Facebook message Monday on her personal page to her friends. "I have been sustained throughout my life by three saving graces – my family, my friends, and a faith in the power of resilience and hope," she wrote. "These graces have carried me through difficult times and they have brought more joy to the good times than I ever could have imagined. The days of our lives, for all of us, are numbered. We know that."
Since 2004, Edwards has struggled with health and marital issues.
John Edwards, who served as North Carolina's senator from 1999 to 2005, launched a White House run with Elizabeth Edwards by his side shortly after President George W. Bush won re-election in 2004. The family practically lived in Iowa leading up to the 2008 Iowa caucus.
In 2007, the couple announced that Elizabeth Edwards' cancer had returned after a period of remission, but they vowed to keep campaigning. John Edwards came in third in that contest behind President Barack Obama and Secretary of State Hillary Clinton.
John and Elizabeth Edwards were always the poster couple for the perfect political marriage. That was the case until summer 2008 when allegations of John Edwards' affair, originally reported in "The National Enquirer" in 2007, bubbled to the mainstream media.
In August 2008, John Edwards admitted the affair with Reille Hunter, who had worked as a video producer in his campaign. Hunter claimed that Edwards was the father of her daughter. Just this past January, John Edwards admitted that he was the father.
John and Elizabeth Edwards have three children. Their oldest son, Wade, was killed in a car wreck in 1996.
Elizabeth Edwards, an attorney, rose to the occasion after her husband's marital infidelity was reported. Already an established author from "Saving Graces," a book about her battle with cancer, Edwards wrote "Resilience: Reflections on the Burdens and Gifts of Facing Life's Adversities" in May 2009.
In that book, she lashed out at Hunter and wrote that her husband should not have run for president in 2008.
For the last several years, Elizabeth Edwards has been a keen activist for women's health care and cancer. She also opened "The Red Window" a furniture store in downtown Chapel Hill last year.
In her Facebook post on Monday, Edwards wrote, "It isn't possible to put into words the love and gratitude I feel to everyone who has and continues to support and inspire me every day," she wrote. "To you I simply say: you know. With love, Elizabeth."
Filed Under: Woman Up
Tagged: Elizabeth Edwards, Elizabeth Edwards Memoir, Elizabeth Edwards Resilience, John Edwards, John Edwards Affair, john kerry, Rielle Hunter
http://www.politicsdaily.com/2010/12/06/elizabeth-edwards-family-gathers-as-her-cancer-spreads/?icid=main%7Chtmlws-main-w%7Cdl1%7Csec3_lnk1%7C188507
I-invest, That was only a cut and paste photo.. I did not write the words and was more interested in the "pull my finger comment"
While I have my political thoughts they do not need to be displayed on this board. I was only pointing out another poor cancer test such as the DRE that Gold is so fond of.
Gold, Maybe you can add this test to your DRE. They look to be of the same caliber.
Prostate Cancer Risk Is Lower in Men With Long Index Fingers, Study Finds
By Marthe Fourcade - Nov 30, 2010 7:01 PM ET
inShare.1More
Men with long index fingers are at lower risk of prostate cancer, a study found.
Scientists in the U.K. who compared the hands of 1,500 prostate cancer patients and 3,000 healthy men found that those whose index was longer than their ring finger were 33 percent less likely to develop the potentially fatal disease.
“Relative finger length could be used as a simple test for prostate cancer risk,” said Ros Eeles, one of the study’s lead authors and a researcher who investigates links between genetic makeup and tumors at London’s Institute of Cancer Research, in a statement. The study was published in the British Journal of Cancer today.
Finger length is set before birth, influenced by the level of sex hormones babies are exposed to in the womb, researchers from the ICR and the University of Warwick in Coventry, England, said in the statement. A longer index finger points to less testosterone, which may protect against cancer later in life, they said.
“Our study indicates it is the hormone levels that babies are exposed to in the womb that can have an effect decades later,” Ken Muir of the University of Warwick, the study’s other lead author, said in the statement. “As our research continues, we will be able to look at a further range of factors that may be involved in the makeup of the disease.”
Scientists from Johns Hopkins University School of Medicine and the U.S. National Institute of Aging in 2004 found that men with high blood levels of testosterone were at increased risk of prostate cancer.
In the study published today, more than half of the men had an index shorter than the ring finger. Those whose two fingers were about equal had a similar prostate cancer risk, the researchers found.
Prostate Action and Cancer Research UK funded the study.
To contact the reporter on this story: Marthe Fourcade at mfourcade@bloomberg.net
To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net
.
Who was it that said one can not patent "monoclonal antibodies"?
The European Medicines Agency’s draft regulation, posted today on the agency’s website, aims to clarify how drugmakers can copy and sell so-called monoclonal antibodies after they lose patent protection. The document is open to public comments until May 31, the London-based agency said.
http://www.bloomberg.com/news/2010-11-25/novartis-teva-may-get-billion-dollar-boost-from-new-eu-rules.html
But what happens if you catch it early?
See link below
http://www.dailyfinance.com/story/the-high-price-of-pet-cancer/19717147/
Gold, I see you are not so bold any longer and are using words like it appears and may have....
I am sure Dr. Moro and his legal advisers have a handle on the business. You might email Dr. Moro with your phone # so that he can call you for advice should he need it in the future when making high priority company decisions.
So Gold, This brings us back to our original discussion.
The Investors Relations Company was not selling the shares....Another of your ASSumptions that was completely incorrect. Must have been your opinion VS. Fact that you have in your disclaimer ey?
Gold stated,"No Half, Opportunity is wrong. There is no "churning" or what ever that means, going on.
Also, if anyone thought or claimed the Investor Relations company just paid 800,000 shares would not be selling them, they would be a blithering idiot."
Gold, were those shares even able to be traded so soon? If not then who would be considered as you say a "blithering idiot"?
Gold, maybe this will clarify the issue (last sentence):
"Form S-8 will remain available to register securities issued as compensation for the services of traditional employees, without regard to the specific character of the service. However, as to consultants and advisors, the character of the service provided will determine whether Form S-8 is available, as described below.
Brokers, dealers and persons who find investors will be excluded from receiving securities registered on Form S-8 because their services, as securities industry professionals, are inherently capital-raising. Consultants who provide investor relations or shareholder communications services also will be excluded, because of the promotional nature of their services.”From http://www.sec.gov/rules/final/33-7646.txt
Gold, maybe this will clarify the issue (last sentence):
"Form S-8 will remain available to register securities issued as compensation for the services of traditional employees, without regard to the specific character of the service. However, as to consultants and advisors, the character of the service provided will determine whether Form S-8 is available, as described below.
Brokers, dealers and persons who find investors will be excluded from receiving securities registered on Form S-8 because their services, as securities industry professionals, are inherently capital-raising. Consultants who provide investor relations or shareholder communications services also will be excluded, because of the promotional nature of their services.”From http://www.sec.gov/rules/final/33-7646.txt
Gold we will just have to agree to disagree.
My source is more credible than yours.
"offering reasonable grounds for being believed"
Gold, If you truly understood the company reports, you would realize that shares for employees or consultants are issued as S-8 forms which could be traded immediately if desired.
The regulations however would specifically forbid the use of S-8 for paying: (a) fees related to raising money and (b) fees for IR activities.
Therfore, any shares going to an investor relations firm would be automatically restricted for 6 months.
Further, I would venture to say that 800,000 shares equal to approximately $40K is really a small amount in the IR business.
So what does a "blithering idiot", as you say, do when found guilty of incorrect assumptions?
I would assume that an apology is in order...Wouldn't you?
Looks to me that Opportunity was 100% correct.
Gold, You are saying that RPC was not telling the truth? And then you want to compare them to Biocurex?
Are you now saying that Biocurex is intentionally deceiving everyone including Goshen / Alere / Abbott / The Russians / The ISOBM....? Wow you are very bold!
Gold stated,"Half, it should be obvious to you and anyone else reading the results, that studies done on behalf of a company or done by the company may not be totally candid."
Gold, were those shares even able to be traded so soon?
If not then who would be considered as you say a "blithering idiot"?
Gold, I understand that you sometimes do not have time to read all of the posts. You apparently missed one of my recent questions so I will repost it for your convenience. I do look forward to your response.http://investorshub.advfn.com/boards/read_msg.aspx?message_id=56493366
Gold...Since you like to compare markers from totally different classes, can You explain the results below using DR-70 in comparison to RECAF's published results?
Also I wondered does this mean that blood clotting increases or decreases with an increase in the stage of cancer?
The following post was penned by some "90 year old guy from New York" or from a 66 year old in CA. Or may be both?
"Since clinical trials are also independently run, I searched the FDA database for the DR70 application. Look at the sensitivity and specificity for the cancer stages 0-2, 3 and 4.
It looks as if the independent research obtaining 70% specificity was not wrong.
Table 11. Results of Sensitivity, Specificity, the Sum of Sensitivity and Specificity, PPV, and
NPV by Cancer Stage
Stage Measure Median Lower 5% Lower 2.5%
Sensitivity 62.50 44.36 40.88
Specificity 60.94 51.19 49.32
Sensitivity + Specificity 123.44 102.84 98.90
PPV 16.67 12.27 11.430-2
NPV 90.70 78.58 76.26
Sensitivity 58.70 47.90 45.83
Specificity 73.08 58.35 55.53
Sensitivity + Specificity 131.77 113.51 110.02
PPV 56.25 49.22 47.87
3
NPV 75.00 63.60 61.40
Sensitivity 69.14 62.68 61.44
Specificity 66.67 59.72 58.40
Sensitivity + Specificity 135.80 126.32 124.51PPV 74.32 68.73 67.65
4
NPV 60.32 54.75 53.69"
No Gold....Opportunity is 100% correct.
Interesting video of cancer cells dividing. See link below.
Gold...Since you like to compare markers from totally different classes, can You explain the results below using DR-70 in comparison to RECAF's published results?
Also I wondered does this mean that blood clotting increases or decreases with an increase in the stage of cancer?
The following post was penned by some "90 year old guy from New York" or from a 66 year old in CA. Or may be both?
"Since clinical trials are also independently run, I searched the FDA database for the DR70 application. Look at the sensitivity and specificity for the cancer stages 0-2, 3 and 4.
It looks as if the independent research obtaining 70% specificity was not wrong.
Table 11. Results of Sensitivity, Specificity, the Sum of Sensitivity and Specificity, PPV, and
NPV by Cancer Stage
Stage Measure Median Lower 5% Lower 2.5%
Sensitivity 62.50 44.36 40.88
Specificity 60.94 51.19 49.32
Sensitivity + Specificity 123.44 102.84 98.90
PPV 16.67 12.27 11.430-2
NPV 90.70 78.58 76.26
Sensitivity 58.70 47.90 45.83
Specificity 73.08 58.35 55.53
Sensitivity + Specificity 131.77 113.51 110.02
PPV 56.25 49.22 47.87
3
NPV 75.00 63.60 61.40
Sensitivity 69.14 62.68 61.44
Specificity 66.67 59.72 58.40
Sensitivity + Specificity 135.80 126.32 124.51PPV 74.32 68.73 67.65
4
NPV 60.32 54.75 53.69"
Read the latest from Biocurex and then the recent article below.
"This is one of our most significant technical advancements since the RECAF cancer test was announced," said BioCurex CEO and President Dr. Ricardo Moro-Vidal. "The product of several years of work, this patent will improve everything we do while reducing the complexity and cost of the process. Most importantly, the granting of this new patent application will extend the life of our current patents by two decades. Furthermore, this peptide opens a wide range of possibilities for delivering killing agents to cancer cells."
By MELLY ALAZRAKI Posted 9:30 AM 08/24/10
Roche Holding (RHHBY), the Swiss pharmaceutical giant and the world's largest maker of cancer drugs, said Tuesday it is entering a deal with U.S.-based Aileron Therapeutics worth up to $1.1 billion to gain access to a new class of drugs called stapled peptide therapeutics.
Cambridge, Mass.-based Aileron is set to get an upfront payment of $25 million and up to $1.1 billion in payments if drug candidates are successfully developed against five targets, as well as royalties on any future sales. The five undisclosed targets will be selected from Roche's key therapeutic areas, which include oncology, virology, inflammation, metabolism and central nervous system.Attacking Intractable Disease Targets
One of the challenges in creating treatment is sometimes the drug's ability to reach and penetrate its target cell. Aileron is working on a technology that can help deliver the drugs.
Aileron aims to develop a stabilized peptide, a small protein. It's doing so by "stapling" the peptide into an alpha-helical shape, which optimizes its ability to link and penetrate the cells, as well as stay active longer. The stapled peptide can therefore help a drug penetrate a cell and remain stable after entry to ensure effective treatment of the patient.The deal with Aileron should help Roche develop a new class of drugs that are based on Aileron's technology and become a potential solution for drugs of intractable disease targets.
"This collaboration with Aileron is a strategically important endeavor for advancing a novel approach to developing new medicines and will accelerate our progress toward our ultimate goal of bringing important new treatments to patients with unmet medical needs," Jean-Jacques Garaud, Global Head of Roche Pharma Research and Early Development said.
The work was in an early stage and clinical trials could start in about three years, Roche spokeswoman Claudia Schmitt told Reuters.
Gold...Are you getting any better at jig saw puzzles?
They do take time to asseble but each piece in place brings one closer to completion of the big picture.
You have figured out the big picture by now..havn't you?
"This is one of our most significant technical advancements since the RECAF cancer test was announced," said BioCurex CEO and President Dr. Ricardo Moro-Vidal. "The product of several years of work, this patent will improve everything we do while reducing the complexity and cost of the process. Most importantly, the granting of this new patent application will extend the life of our current patents by two decades. Furthermore, this peptide opens a wide range of possibilities for delivering killing agents to cancer cells."
Interesting World Clock that includes Cancer rate worldwide...Cancer deaths etc.
http://www.poodwaddle.com/clocks/worldclock/